LBOACP: Lymph Node Dissection Before Or After Cystectomy

Sponsor
Jagiellonian University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05939856
Collaborator
(none)
50
2
17.1

Study Details

Study Description

Brief Summary

The purpose of this study is to compare different ways of performing surgery for bladder cancer. Specifically, the goal is to determine whether it is better to remove the lymph nodes before removing the bladder or after removing the bladder during radical cystectomy.

The study aims to answer two main questions:
  • Does the order of surgical steps during radical cystectomy affect the occurrence of complications after surgery?

  • Does the order of surgical steps during radical cystectomy impact the duration of the operation and the number of lymph nodes removed?

Participants in the study will be randomly assigned to one of two groups. One group will undergo lymph node removal before bladder resection, while the other group will have lymph node removal after bladder resection during radical cystectomy.

Throughout their hospital stay and for 30 days following the operation, participants will be closely monitored for various factors including operative details, pathology results, and any complications that may arise.

Condition or Disease Intervention/Treatment Phase
  • Other: Lymph node dissection before bladder resection
  • Other: Lymph node dissection after bladder resection
N/A

Detailed Description

Lymph node dissection (LND) is an integral part of radical cystectomy (RC) for bladder cancer. LND provides important diagnostic and prognostic information, and according to most studies, is associated with therapeutic benefit. The optimal extent and template for LND in bladder cancer remains to be established. Currently, there are no specific recommendations regarding the sequence of lymph nodes removal and bladder resection during radical cystectomy, and the decision is based mainly on individual surgeon preference.

The aim of the LBOAC pilot randomized trial is to evaluate the difference in intraoperative parameters and postoperative outcomes between patients undergoing LND before bladder resection during RC and those undergoing LND after bladder resection during RC.

LBOAC is a pilot randomized controlled trial with two parallel groups. The primary objective of the trial is the comparison of complication rate within 30 postoperative days. Secondary objectives of LBOAC include comparing lymph node yield and operative time between the two groups.

Data for will be collected using electronic case report forms (eCRFs) at baseline and within 30 days after the surgery.

This pilot study is designed to test feasibility of, to support the refinements of the protocol and to aid in sample calculation that can be used for larger scale trial.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Lymph Node Dissection Before Or After Cystectomy - Pilot Randomized Controlled Trial
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: 1 Lymph node dissection before bladder resection

Lymph node dissection will be performed before bladder resection during radical cystectomy

Other: Lymph node dissection before bladder resection
Lymph node dissection before bladder resection

Other: 2 Lymph node dissection after bladder resection

Lymph node dissection will be performed after bladder resection during radical cystectomy

Other: Lymph node dissection after bladder resection
Lymph node dissection after bladder resection

Outcome Measures

Primary Outcome Measures

  1. Early complications rate [Within 30 days after the surgery]

    Complications rate within 30 postoperative days

Secondary Outcome Measures

  1. Lymph node yield [When pathology report is available (on average, the pathology report is available within 14 days after the surgery)]

    Number of lymph nodes removed

  2. Operative time [At the end of the surgery (after the completion of skin closure and wound dressing)]

    Total operative time, bladder resection time, lymph node dissection time

Other Outcome Measures

  1. Intraoperative complications rate [At the end of the surgery (after the completion of skin closure and wound dressing)]

    Intraoperative complications rate

  2. Positive surgical margin rate [When pathology report is available (on average, the pathology report is available within 14 days after the surgery)]

    Positive surgical margin rate

  3. Ureters clamping time [At the end of the surgery (after the completion of skin closure and wound dressing)]

    Ureters clamping time

  4. Postoperative estimated glomerular filtration rate (eGFR) [Within 7 days after the surgery]

    eGFR on postoperative day 1 and day 4-7

  5. Complications severity and type [Within 30 days after the surgery]

    Severity and type of complications

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients undergoing radical cystectomy for bladder cancer in the Department of Urology University Hospital in Krakow
Exclusion Criteria:
  • Previous pelvic lymph node dissection

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Jagiellonian University

Investigators

  • Principal Investigator: Anna K. Czech, Jagiellonian University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Anna K. Czech, MD, Principal Investigator, Jagiellonian University
ClinicalTrials.gov Identifier:
NCT05939856
Other Study ID Numbers:
  • LBOACPUJ
First Posted:
Jul 11, 2023
Last Update Posted:
Jul 11, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Anna K. Czech, MD, Principal Investigator, Jagiellonian University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 11, 2023